Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Codexis to Participate in TD Cowen 44th Annual Health Care Conference
By: GlobeNewswire - 26 Feb 2024Back to overview list

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.

Management will participate in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET. A live webcast of the event will be available here and in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 90 days following the event.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com


Related companies:Codexis, Inc.
Copyright 2024 GlobeNewswire Back to overview list
to the top ↑